The impact of obesity as a comorbid condition in RA has been more extensively analyzed in the treatment with TNF inhibitors (TNFi), and there are currently numerous studies in which a higher BMI implies a worse response to bDMARDs, regardless of the route of administration [17,18,19]. Here, TNF is linked to obesity due to melanocortin 4 receptor deficiency.